RESUMO
Background: Brain-lung-thyroid syndrome (BLTS) is caused by NKX2-1 haploinsufficiency, resulting in chorea/choreoathetosis, respiratory problems, and hypothyroidism. Genes interacting with NKX2-1 mutants influence its phenotypic variability. We report a novel NKX2-1 missense variant and the modifier function of TAZ/WWTR1 in BLTS. Methods: A child with BLTS underwent next-generation sequencing panel testing for thyroid disorders. His family was genotyped for NKX2-1 variants and screened for germline mosaicism. Mutant NKX2-1 was generated, and transactivation assays were performed on three NKX2-1 target gene promoters. DNA binding capacity and protein-protein interaction were analyzed. Results: The patient had severe BLTS and carried a novel missense variant c.632A>G (p.N211S) in NKX2-1, which failed to bind to specific DNA promoters, reducing their transactivation. TAZ cotransfection did not significantly increase transcription of these genes, although the variant retained its ability to bind to TAZ. Conclusions: We identify a novel pathogenic NKX2-1 variant that causes severe BLTS and is inherited through germline mosaicism. The mutant lacks DNA-binding capacity, impairing transactivation and suggesting that NKX2-1 binding to DNA is essential for TAZ-mediated transcriptional rescue.
Assuntos
Mutação de Sentido Incorreto , Fator Nuclear 1 de Tireoide , Transativadores , Proteínas com Motivo de Ligação a PDZ com Coativador Transcricional , Humanos , Masculino , Fator Nuclear 1 de Tireoide/genética , Fator Nuclear 1 de Tireoide/metabolismo , Transativadores/genética , Ativação Transcricional , Coreia/genética , Fatores de Transcrição/genética , Peptídeos e Proteínas de Sinalização Intracelular/genética , Atetose , Hipotireoidismo Congênito , Síndrome do Desconforto Respiratório do Recém-NascidoRESUMO
BACKGROUND: Anal squamous cell carcinoma (ASCC) is an infrequent tumor whose treatment has not changed since the 1970s. The aim of this study is the identification of biomarkers allowing personalized treatments and improvement of therapeutic outcomes. METHODS: Forty-six paraffin tumor samples from ASCC patients were analyzed by whole-exome sequencing. Copy number variants (CNVs) were identified and their relation to disease-free survival (DFS) was studied and validated in an independent retrospective cohort of 101 ASCC patients from the Multidisciplinary Spanish Digestive Cancer Group (GEMCAD). GEMCAD cohort proteomics allowed assessing the biological features of these tumors. RESULTS: On the discovery cohort, the median age was 61 years old, 50% were males, stages I/II/III: 3 (7%)/16 (35%)/27 (58%), respectively, median DFS was 33 months, and overall survival was 45 months. Twenty-nine genes whose duplication was related to DFS were identified. The most representative was duplications of the CYP2D locus, including CYP2D6, CYP2D7P, and CYP2D8P genes. Patients with CYP2D6 CNV had worse DFS at 5 years than those with two CYP2D6 copies (21% vs. 84%; p < .0002, hazard ratio [HR], 5.8; 95% confidence interval [CI], 2.7-24.9). In the GEMCAD validation cohort, patients with CYP2D6 CNV also had worse DFS at 5 years (56% vs. 87%; p = .02, HR = 3.6; 95% CI, 1.1-5.7). Mitochondria and mitochondrial cell-cycle proteins were overexpressed in patients with CYP2D6 CNV. CONCLUSIONS: Tumor CYP2D6 CNV identified patients with a significantly worse DFS at 5 years among localized ASCC patients treated with 5-fluorouracil, mitomycin C, and radiotherapy. Proteomics pointed out mitochondria and mitochondrial cell-cycle genes as possible therapeutic targets for these high-risk patients. PLAIN LANGUAGE SUMMARY: Anal squamous cell carcinoma is an infrequent tumor whose treatment has not been changed since the 1970s. However, disease-free survival in late staged tumors is between 40% and 70%. The presence of an alteration in the number of copies of CYP2D6 gene is a biomarker of worse disease-free survival. The analysis of the proteins in these high-risk patients pointed out mitochondria and mitochondrial cell-cycle genes as possible therapeutic targets. Therefore, the determination of the number of copies of CYP2D6 allows the identification of anal squamous carcinoma patients with a high-risk of relapse that could be redirected to a clinical trial. Additionally, this study may be useful to suggest new treatment strategies to increase current therapy efficacy.
Assuntos
Neoplasias do Ânus , Carcinoma de Células Escamosas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias do Ânus/genética , Neoplasias do Ânus/terapia , Neoplasias do Ânus/patologia , Biomarcadores , Carcinoma de Células Escamosas/terapia , Carcinoma de Células Escamosas/tratamento farmacológico , Citocromo P-450 CYP2D6/genética , Variações do Número de Cópias de DNA , Recidiva Local de Neoplasia/patologia , Prognóstico , Estudos RetrospectivosRESUMO
Wounds represent a medical problem that contributes importantly to patient morbidity and to healthcare costs in several pathologies. In Hidalgo, Mexico, the Bacopa procumbens plant has been traditionally used for wound-healing care for several generations; in vitro and in vivo experiments were designed to evaluate the effects of bioactive compounds obtained from a B. procumbens aqueous fraction and to determine the key pathways involved in wound regeneration. Bioactive compounds were characterized by HPLC/QTOF-MS, and proliferation, migration, adhesion, and differentiation studies were conducted on NIH/3T3 fibroblasts. Polyphenolic compounds from Bacopa procumbens (PB) regulated proliferation and cell adhesion; enhanced migration, reducing the artificial scratch area; and modulated cell differentiation. PB compounds were included in a hydrogel for topical administration in a rat excision wound model. Histological, histochemical, and mechanical analyses showed that PB treatment accelerates wound closure in at least 48 h and reduces inflammation, increasing cell proliferation and deposition and organization of collagen at earlier times. These changes resulted in the formation of a scar with better tensile properties. Immunohistochemistry and RT-PCR molecular analyses demonstrated that treatment induces (i) overexpression of transforming growth factor beta (TGF-ß) and (ii) the phosphorylation of Smad2/3 and ERK1/2, suggesting the central role of some PB compounds to enhance wound healing, modulating TGF-ß activation.
Assuntos
Bacopa , Plantaginaceae , Animais , Colágeno/metabolismo , Fibroblastos , Hidrogéis/farmacologia , Ratos , Pele , Fator de Crescimento Transformador beta/metabolismo , CicatrizaçãoRESUMO
EVEN-PLUS syndrome is a rare autosomal recessive disorder caused by biallelic pathogenic variants in the mitochondrial chaperone called mortalin, encoded by HSPA9. This genetic disorder, presenting with several overlapping features with CODAS syndrome, is characterized by the involvement of the Epiphyses, Vertebrae, Ears, and Nose (EVEN), PLUS associated findings. Only five individuals presenting with the EVEN-PLUS phenotype and biallelic variants in HSPA9 have been published. Here, we expand the phenotypic and molecular spectrum associated with this disorder, reporting two sibs with a milder phenotype and compound heterozygous pathogenic variants (a recurrent variant and a novel one). Also, we confirm a homozygous pathogenic variant in the family originally reported as EVE dysplasia.
Assuntos
Anormalidades Craniofaciais , Osteocondrodisplasias , Anormalidades Dentárias , Anormalidades Craniofaciais/diagnóstico , Anormalidades Craniofaciais/genética , Proteínas de Choque Térmico HSP70/genética , Homozigoto , Humanos , Proteínas Mitocondriais/genética , Osteocondrodisplasias/diagnóstico , Osteocondrodisplasias/genética , FenótipoRESUMO
Posterior polymorphous corneal dystrophy (PPCD), a rare, bilateral, autosomal-dominant, inherited corneal dystrophy, affects the Descemet membrane and corneal endothelium. We describe an unusual presentation of PPCD associated with a previously unknown genetic alteration in the ZEB1 gene. The proband is a 64-year-old woman diagnosed with keratoconus referred for a corneal endothelium study who presented endothelial lesions in both eyes suggestive of PPCD, corectopia and iridocorneal endothelial synechiae in the right eye and intrastromal segments in the left eye. The endothelial count was 825 in the right eye and 1361 in the left eye, with typical PPCD lesions visible under specular and confocal microscopy. In the next generation sequencing genetic analysis, a heterozygous c.1A > C (p.Met1Leu) mutation was found in the ZEB1 gene (TCF8). The PPCD3 subtype is associated with corneal ectasia, and both can appear due to a pathogenic mutation in the ZEB1 gene (OMIM #189909). However, our patient had a previously unreported mutation in the ZEB1 gene, which mediates the transition between cell lines and provides a pathogenic explanation for the epithelialisation of the corneal endothelium, a characteristic of PPCD.
Assuntos
Distrofias Hereditárias da Córnea , Proteínas de Homeodomínio , Feminino , Humanos , Pessoa de Meia-Idade , Proteínas de Homeodomínio/genética , Proteínas de Homeodomínio/metabolismo , Fatores de Transcrição/metabolismo , Homeobox 1 de Ligação a E-box em Dedo de Zinco/genética , Homeobox 1 de Ligação a E-box em Dedo de Zinco/metabolismo , Distrofias Hereditárias da Córnea/genética , Distrofias Hereditárias da Córnea/patologia , Endotélio Corneano/metabolismo , MutaçãoRESUMO
OBJECTIVE: Next generation sequencing (NGS) has expanded the diagnostic paradigm turning the focus to the growth plate. The aim of the study was to determine the prevalence of variants in genes implicated in skeletal dysplasias in probands with short stature and mild skeletal anomalies. DESIGN: Clinical and radiological data were collected from 108 probands with short stature and mild skeletal anomalies. METHODS: A customized skeletal dysplasia NGS panel was performed. Variants were classified using ACMG recommendations and Sherloc. Anthropometric measurements and skeletal anomalies were subsequently compared in those with or without an identified genetic defect. RESULTS: Heterozygous variants were identified in 21/108 probands (19.4%). Variants were most frequently identified in ACAN (n = 10) and IHH (n = 7) whilst one variant was detected in COL2A1, CREBBP, EXT1, and PTPN11. Statistically significant differences (P < 0.05) were observed for sitting height/height (SH/H) ratio, SH/H ratio standard deviation score (SDS), and the SH/H ratio SDS >1 in those with an identified variant compared to those without. CONCLUSIONS: A molecular defect was elucidated in a fifth of patients. Thus, the prevalence of mild forms of skeletal dysplasias is relatively high in individuals with short stature and mild skeletal anomalies, with variants in ACAN and IHH accounting for 81% of the cases. An elevated SH/H ratio appears to be associated with a greater probability in detecting a variant, but no other clinical or radiological feature has been found determinant to finding a genetic cause. Currently, we cannot perform extensive molecular studies in all short stature individuals so detailed clinical and radiological phenotyping may orientate which are the candidate patients to obtain worthwhile results. In addition, detailed phenotyping of probands and family members will often aid variant classification.
Assuntos
Estatura/genética , Osso e Ossos/anormalidades , Nanismo/genética , Osteocondrodisplasias/genética , Adolescente , Antropometria , Criança , Pré-Escolar , Feminino , Variação Genética , Lâmina de Crescimento/anormalidades , Heterozigoto , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Lactente , Masculino , Linhagem , PrevalênciaRESUMO
Mosaic Variegated Aneuploidy Syndrome 2 (MVA2; MIM 614114) is a rare autosomal recessive disorder, characterized by mosaic aneuploidies involving multiple chromosomes and tissues, caused by biallelic pathogenic variants in the CEP57 gene. Only 10 patients have been reported to date. We report two additional non related cases born to Moroccan consanguineous parents, carrying the previously described c.915_925dup11 CEP57 homozygous variant. Common features of these 12 cases include growth retardation, typically of prenatal onset, distinctive facial features, endocrine, cardiovascular and skeletal, abnormalities while malignancies have not been reported. This report describes the phenotypical spectrum of MVA2.
Assuntos
Transtornos Cromossômicos/genética , Proteínas Associadas aos Microtúbulos/genética , Proteínas Nucleares/genética , Fenótipo , Criança , Transtornos Cromossômicos/patologia , Humanos , Masculino , Mosaicismo , MutaçãoRESUMO
Stuve-Wiedemann syndrome (SWS; MIM 601559) is a rare autosomal recessive disease caused by mutations in the leukemia inhibitor factor receptor gene (LIFR). Common clinical and radiological findings are often observed, and high neonatal mortality occurs due to respiratory distress and hyperthermic episodes. Despite initially considered as a lethal disorder during the newborn period, in recent years, several SWS childhood survivors have been reported. We report a detailed clinical and radiological characterization of four unrelated childhood SWS molecularly confirmed patients and review 22 previously reported childhood surviving cases. We contribute to the definition of the childhood survival phenotype of SWS, emphasizing the evolving phenotype, characterized by skeletal abnormalities with typical radiological findings, distinctive dysmorphic features, and dysautonomia. Based on the typical features and clinical course, early diagnosis is possible and crucial to plan appropriate management and prevent potential complications. Genetic confirmation is advisable in order to improve genetic counseling to the patients and their families.
Assuntos
Anormalidades Múltiplas/genética , Doenças do Desenvolvimento Ósseo/genética , Exostose Múltipla Hereditária/diagnóstico por imagem , Subunidade alfa de Receptor de Fator Inibidor de Leucemia/genética , Osteocondrodisplasias/diagnóstico por imagem , Doenças do Desenvolvimento Ósseo/diagnóstico por imagem , Doenças Ósseas Metabólicas/genética , Pré-Escolar , Consanguinidade , Deficiências do Desenvolvimento/genética , Disautonomia Familiar/genética , Exostose Múltipla Hereditária/genética , Exostose Múltipla Hereditária/patologia , Feminino , Genótipo , Humanos , Lactente , Recém-Nascido , Subunidade alfa de Receptor de Fator Inibidor de Leucemia/deficiência , Masculino , Hipotonia Muscular/genética , Osteocondrodisplasias/genética , Osteocondrodisplasias/patologia , Fenótipo , Roma (Grupo Étnico)/genética , SobreviventesRESUMO
CONTEXT: Heterozygous variants in the Indian hedgehog gene (IHH) have been reported to cause brachydactyly type A1 and mild hand and feet skeletal anomalies with short stature. Genetic screening in individuals with short stature and mild skeletal anomalies has been increasing over recent years, allowing us to broaden the clinical spectrum of skeletal dysplasias. OBJECTIVE: The objective of this article is to describe the genotype and phenotype of 16 probands with heterozygous variants in IHH. PATIENTS AND METHODS: Targeted next-generation sequencing or Sanger sequencing was performed in patients with short stature and/or brachydactyly for which the genetic cause was unknown. RESULTS: Fifteen different heterozygous IHH variants were detected, one of which is the first reported complete deletion of IHH. None of the patients showed the classical phenotype of brachydactyly type A1. The most frequently observed clinical characteristics were mild to moderate short stature as well as shortening of the middle phalanx on the fifth finger. The identified IHH variants were demonstrated to cosegregate with the short stature and/or brachydactyly in the 13 probands whose family members were available. However, clinical heterogeneity was observed: Two short-statured probands showed no hand radiological anomalies, whereas another 5 were of normal height but had brachydactyly. CONCLUSIONS: Short stature and/or mild skeletal hand defects can be caused by IHH variants. Defects in this gene should be considered in individuals with these findings, especially when there is an autosomal dominant pattern of inheritance. Although no genotype-phenotype correlation was observed, cosegregation studies should be performed and where possible functional characterization before concluding that a variant is causative.
Assuntos
Estatura/genética , Braquidactilia/genética , Proteínas Hedgehog/genética , Adolescente , Braquidactilia/diagnóstico , Criança , Pré-Escolar , Estudos de Coortes , Análise Mutacional de DNA , Feminino , Mãos/diagnóstico por imagem , Humanos , Lactente , Masculino , Mutação , Linhagem , Polimorfismo de Nucleotídeo Único , RadiografiaRESUMO
Tatton-Brown-Rahman (TBRS) syndrome is a recently described overgrowth syndrome caused by loss of function variants in the DNMT3A gene. This gene encodes for a DNA methyltransferase 3 alpha, which is involved in epigenetic regulation, especially during embryonic development. Somatic variants in DNMT3A have been widely studied in different types of tumors, including acute myeloid leukemia, hematopoietic, and lymphoid cancers. Germline gain-of-function variants in this gene have been recently implicated in microcephalic dwarfism. Common clinical features of patients with TBRS include tall stature, macrocephaly, intellectual disability (ID), and a distinctive facial appearance. Differential diagnosis of TBRS comprises Sotos, Weaver, and Malan Syndromes. The majority of these disorders present other clinical features with a high clinical overlap, making necessary a molecular confirmation of the clinical diagnosis. We here describe seven new patients with variants in DNMT3A, four of them with neuropsychiatric disorders, including schizophrenia and psychotic behavior. In addition, one of the patients has developed a brain tumor in adulthood. This patient has also cerebral atrophy, aggressive behavior, ID, and abnormal facial features. Clinical evaluation of this group of patients should include a complete neuropsychiatric assessment together with psychological support in order to detect and manage abnormal behaviors such as aggressiveness, impulsivity, and attention deficit-hyperactivity disorder. TBRS should be suspected in patients with overgrowth, ID, tall stature, and macrocephaly, who also have some neuropsychiatric disorders without any genetic defects in the commonest overgrowth disorders. Molecular confirmation in these patients is mandatory.
Assuntos
DNA (Citosina-5-)-Metiltransferases/genética , Transtornos do Crescimento/genética , Deficiência Intelectual/genética , Fenótipo , Transtornos Psicóticos/genética , Adolescente , Adulto , Criança , DNA Metiltransferase 3A , Feminino , Transtornos do Crescimento/patologia , Humanos , Deficiência Intelectual/patologia , Masculino , Pessoa de Meia-Idade , Mutação , Transtornos Psicóticos/patologia , SíndromeRESUMO
Overgrowth syndromes (OGS) comprise a heterogeneous group of disorders whose main characteristic is that either the weight, height, or head circumference are above the 97th centile or 2 to 3 SD above the mean for age and sex. Additional features, such as facial dysmorphism, developmental delay or intellectual disability (ID), congenital anomalies, neurological problems and an increased risk of neoplasia are usually associated with OGS. Genetic analysis in patients with overlapping clinical features is essential, to distinguish between two or more similar conditions, and to provide appropriate genetic counseling and recommendations for follow up. In the present paper, we report five new patients (from four unrelated families) with an X-linked mental retardation syndrome with overgrowth (XMR93 syndrome), also known as XLID-BRWD3-related syndrome. The main features of these patients include ID, macrocephaly and dysmorphic facial features. XMR93 syndrome is a recently described disorder caused by mutations in the Bromodomain and WD-repeat domain-containing protein 3 (BRWD3) gene. This article underscores the importance of genetic screening by exome sequencing for patients with OGS and ID with unclear clinical diagnosis, and expands the number of reported individuals with XMR93 syndrome, highlighting the clinical features of this unusual disease.
Assuntos
Megalencefalia/genética , Deficiência Intelectual Ligada ao Cromossomo X/genética , Fatores de Transcrição/genética , Anormalidades Múltiplas/genética , Adolescente , Adulto , Criança , Deficiências do Desenvolvimento , Humanos , Masculino , Megalencefalia/metabolismo , Megalencefalia/fisiopatologia , Deficiência Intelectual Ligada ao Cromossomo X/fisiopatologia , Mutação , Linhagem , Sistema de Registros , Fatores de Transcrição/metabolismo , Sequenciamento do ExomaRESUMO
PURPOSE: The goal of this study was to assess the experimental feasibility of circular multistatic holography, a novel breast microwave radar reconstruction approach, using experimental datasets recorded using a preclinical experimental setup. The performance of this approach was quantitatively evaluated by calculating the signal to clutter ratio (SCR), contrast to clutter ratio (CCR), tumor to fibroglandular response ratio (TFRR), spatial accuracy, and reconstruction time. METHODS: Five datasets were recorded using synthetic phantoms with the dielectric properties of breast tissue in the 1-6 GHz range using a custom radar system developed by the authors. The datasets contained synthetic structures that mimic the dielectric properties of fibroglandular breast tissues. Four of these datasets the authors covered an 8 mm inclusion that emulated a tumor. A custom microwave radar system developed at the University of Manitoba was used to record the radar responses from the phantoms. The datasets were reconstructed using the proposed multistatic approach as well as with a monostatic holography approach that has been previously shown to yield the images with the highest contrast and focal quality. RESULTS: For all reconstructions, the location of the synthetic tumors in the experimental setup was consistent with the position in the both the monostatic and multistatic reconstructed images. The average spatial error was less than 4 mm, which is half the spatial resolution of the data acquisition system. The average SCR, CCR, and TFRR of the images reconstructed with the multistatic approach were 15.0, 9.4, and 10.0 dB, respectively. In comparison, monostatic images obtained using the datasets from the same experimental setups yielded average SCR, CCR, and TFRR values of 12.8, 4.9, and 5.9 dB. No artifacts, defined as responses generated by the reconstruction method of at least half the energy of the tumor signatures, were noted in the multistatic reconstructions. The average execution time of the images formed using the proposed approach was 4 s, which is one order of magnitude faster than the current state-of-the-art time-domain multistatic breast microwave radar reconstruction algorithms. CONCLUSIONS: The images generated by the proposed method show that multistatic holography is capable of forming spatially accurate images in real-time with signal to clutter levels and contrast values higher than other published monostatic and multistatic cylindrical radar reconstruction approaches. In comparison to the monostatic holographic approach, the images generated by the proposed multistatic approach had SCR values that were at least 50% higher. The multistatic images had CCR and TFRR values at least 200% greater than those formed using a monostatic approach.
Assuntos
Mama/diagnóstico por imagem , Holografia , Processamento de Imagem Assistida por Computador/métodos , Micro-Ondas , Radar , Neoplasias da Mama/diagnóstico por imagem , Estudos de ViabilidadeRESUMO
OBJECTIVES: Biallelic mutations in the ARG1 gene result in an uncommon autosomal recessive inborn defect of the urea cycle known as hyperargininemia (OMIM #207800). ARG1 splicing mutations are not reported often, and they are probably related to a more severe phenotype than missense mutations. In this article, we describe the results of molecular studies in a young hyperargininemia patient carrying a novel splicing mutation in ARG1. DESIGN AND METHODS: Molecular analyses included PCR amplification and direct nucleotide sequencing of the ARG1 gene. RT-PCR analysis was performed to investigate the effect of the mutation in mRNA splicing and in the expression of ARG1 isoforms. RESULTS: Mutational analysis identified a novel homozygous ARG1 IVS4-1G>C point mutation in the patient's DNA. Blood leukocyte mRNA was analyzed to demonstrate the splicing defect caused by this mutation. Sequencing of ARG1 RT-PCR products allowed the characterization of a mutated transcript retaining 51-bp from intron 4. In addition, two new, alternatively spliced ARG1 transcripts lacking either exon 4 or exons 4 and 5 were identified in mRNA from the patient and from controls. CONCLUSIONS: Our results expand the mutational spectrum in hyperargininemia patients and indicate that the novel splicing mutation results in an aberrant transcript retaining intronic sequences. Two novel alternatively spliced ARG1 transcripts were also recognized.
Assuntos
Arginase/genética , Hiperargininemia/diagnóstico , Hiperargininemia/genética , Mutação Puntual , RNA Mensageiro/genética , Processamento Alternativo , Sequência de Bases , Éxons , Homozigoto , Humanos , Hiperargininemia/patologia , Lactente , Íntrons , Isoenzimas/genética , Masculino , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Análise de Sequência de DNARESUMO
In this study, we evaluated the effect of an analogue of l-carnitine on parameters involved with Metabolic Syndrome in obese Zucker rats. Twenty-four rats were treated for 5 weeks with l-carnitine (300 mg/kg) and its analogue at two concentrations (100 and 250 mg/kg) to assess their impact on glucose, triglycerides and cholesterol in liver and blood samples, as well as the amount of liver glycogen. Liver slices were also analysed. The analogue reduced the levels of glucose, triglycerides and cholesterol in liver and the level of triglycerides in serum. At 100 mg/kg, the analogue proved more effective than l-carnitine in improving the biochemical alterations present in liver. The amount of liver glycogen content was higher in obese animals treated with both l-carnitine and the analogue. No changes on insulin and leptin were observed in animals treated. l-carnitine and its analogue reduced the microvesicular fatty infiltration in liver. This study demonstrated that the analogue tested is more potent and efficient than l-carnitine and improves the pharmacological profile of l-carnitine.
Assuntos
Carnitina/farmacologia , Fígado/efeitos dos fármacos , Síndrome Metabólica/tratamento farmacológico , Obesidade/tratamento farmacológico , Animais , Carnitina/administração & dosagem , Carnitina/análogos & derivados , Colesterol/metabolismo , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Glucose/metabolismo , Glicogênio/metabolismo , Insulina/metabolismo , Leptina/metabolismo , Fígado/metabolismo , Masculino , Ratos , Ratos Zucker , Triglicerídeos/metabolismoRESUMO
Se presenta un caso clínico con fibroma de gran tamaño, 10 x 5 x 4 cm. dentro de boca. Los autores consultados coinciden en que este tipo de lesiones miden milímetros generalmente y en muy raras ocasiones llegan a medir centímetros. Por el tamaño de esta lesión se considera interesante comunicarlo a la comunidad odontológica